Anthropic's Claude has optimized over 30 open-source biomolecular modeling tools, achieving roughly 4x average speedup and creating a low-memory mode for larger predictions on single GPU nodes. The company is open-sourcing the optimized code and launching a protein design competition with Adaptyv Bio offering up to $1 million in Claude credits and wet lab validation for over 5,000 designs.
AI has accelerated progress in mathematical proofs but lags significantly in drug discovery and experimental biology, according to a Google-MIT study. Scientists report that AI has shifted bottlenecks toward physical experimentation and data collection, while many spend substantial time verifying AI outputs. Technical and practical hurdles—including automation limitations, data scarcity, and the complexity of real-world experiments—explain why AI hasn't yet transformed experimental sciences despite government emphasis on its potential.
Popular DeFi discussions from September 20, 2026 cover Anthropic's optimization of biology models for drug discovery in partnership with Adaptyv Bio, analysis of Atmos Protocol's growing metrics and infrastructure potential on Supra, critique of how protocol revenue metrics mislead token holders about value capture, and commentary on Cardano DeFi competitiveness.
Nvidia expanded its open-source CUDA-Q platform with a new Logical orchestration layer enabling researchers to design and test fault-tolerant quantum computing applications. Fermilab achieved a 7x speedup in algorithm development using the tool, reducing timelines from five months to three weeks. Sandia National Laboratories developed QUOPS, a benchmark for measuring quantum hardware readiness for practical applications, now integrated into CUDA-Q.